Konstantinos Votanopoulos
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hyperthermia, Induced | 39 | 2019 | 235 | 12.430 |
Why?
|
| Peritoneal Neoplasms | 38 | 2019 | 241 | 11.970 |
Why?
|
| Chemotherapy, Cancer, Regional Perfusion | 28 | 2019 | 146 | 8.390 |
Why?
|
| Stomach Neoplasms | 36 | 2019 | 85 | 6.360 |
Why?
|
| Appendiceal Neoplasms | 16 | 2019 | 81 | 6.280 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 21 | 2019 | 401 | 5.600 |
Why?
|
| Neoplasm Recurrence, Local | 26 | 2019 | 337 | 4.600 |
Why?
|
| Adenocarcinoma | 33 | 2018 | 301 | 4.500 |
Why?
|
| Gastrectomy | 29 | 2019 | 65 | 3.650 |
Why?
|
| Survival Rate | 58 | 2019 | 795 | 3.320 |
Why?
|
| Antineoplastic Agents | 14 | 2019 | 546 | 2.960 |
Why?
|
| Sarcoma | 11 | 2019 | 56 | 2.920 |
Why?
|
| Neoplasm Staging | 45 | 2019 | 436 | 2.800 |
Why?
|
| Combined Modality Therapy | 30 | 2019 | 525 | 2.760 |
Why?
|
| Prognosis | 56 | 2019 | 1362 | 2.740 |
Why?
|
| Retrospective Studies | 60 | 2019 | 3111 | 2.650 |
Why?
|
| Adrenal Cortex Neoplasms | 18 | 2019 | 34 | 2.620 |
Why?
|
| Adrenocortical Carcinoma | 18 | 2019 | 34 | 2.620 |
Why?
|
| Follow-Up Studies | 45 | 2019 | 2108 | 2.450 |
Why?
|
| Postoperative Complications | 21 | 2018 | 670 | 2.290 |
Why?
|
| Neoplasms | 7 | 2017 | 610 | 2.270 |
Why?
|
| Middle Aged | 93 | 2019 | 10829 | 2.190 |
Why?
|
| Lymph Node Excision | 11 | 2019 | 89 | 2.130 |
Why?
|
| Male | 103 | 2019 | 17807 | 1.940 |
Why?
|
| Female | 103 | 2019 | 18164 | 1.870 |
Why?
|
| Humans | 119 | 2019 | 29093 | 1.780 |
Why?
|
| Chemotherapy, Adjuvant | 21 | 2019 | 163 | 1.760 |
Why?
|
| Mesothelioma | 5 | 2019 | 38 | 1.740 |
Why?
|
| Carcinoma | 5 | 2016 | 87 | 1.580 |
Why?
|
| Colonic Neoplasms | 3 | 2016 | 63 | 1.500 |
Why?
|
| Adult | 56 | 2019 | 8420 | 1.450 |
Why?
|
| Pancreatectomy | 4 | 2019 | 29 | 1.440 |
Why?
|
| Aged | 64 | 2019 | 9487 | 1.400 |
Why?
|
| Prospective Studies | 18 | 2019 | 2019 | 1.390 |
Why?
|
| Morbidity | 9 | 2017 | 91 | 1.160 |
Why?
|
| Drug Screening Assays, Antitumor | 3 | 2019 | 50 | 1.000 |
Why?
|
| Aged, 80 and over | 27 | 2019 | 3717 | 1.000 |
Why?
|
| Adrenalectomy | 8 | 2018 | 29 | 0.950 |
Why?
|
| Mitomycin | 5 | 2018 | 45 | 0.930 |
Why?
|
| Abdominal Neoplasms | 4 | 2018 | 15 | 0.910 |
Why?
|
| Treatment Outcome | 24 | 2019 | 3099 | 0.890 |
Why?
|
| United States | 38 | 2019 | 3630 | 0.890 |
Why?
|
| Splenectomy | 4 | 2019 | 19 | 0.880 |
Why?
|
| Retroperitoneal Neoplasms | 2 | 2019 | 11 | 0.870 |
Why?
|
| Liver Neoplasms | 4 | 2018 | 162 | 0.830 |
Why?
|
| Young Adult | 15 | 2019 | 2402 | 0.810 |
Why?
|
| Organoids | 2 | 2018 | 68 | 0.790 |
Why?
|
| Registries | 3 | 2018 | 278 | 0.750 |
Why?
|
| Adenocarcinoma, Mucinous | 2 | 2017 | 20 | 0.750 |
Why?
|
| Lymph Nodes | 6 | 2018 | 92 | 0.740 |
Why?
|
| Survival Analysis | 13 | 2016 | 440 | 0.730 |
Why?
|
| Colorectal Neoplasms | 7 | 2019 | 208 | 0.710 |
Why?
|
| Peritoneum | 3 | 2013 | 24 | 0.670 |
Why?
|
| Organoplatinum Compounds | 3 | 2013 | 42 | 0.660 |
Why?
|
| Databases, Factual | 10 | 2018 | 332 | 0.640 |
Why?
|
| Intensive Care Units | 2 | 2015 | 118 | 0.630 |
Why?
|
| Diaphragm | 2 | 2014 | 46 | 0.600 |
Why?
|
| Intestinal Perforation | 1 | 2016 | 9 | 0.590 |
Why?
|
| Lymphatic Metastasis | 12 | 2018 | 156 | 0.580 |
Why?
|
| Models, Biological | 1 | 2018 | 373 | 0.570 |
Why?
|
| Cell Proliferation | 1 | 2018 | 573 | 0.560 |
Why?
|
| Linitis Plastica | 1 | 2015 | 2 | 0.550 |
Why?
|
| Ovarian Neoplasms | 1 | 2016 | 87 | 0.550 |
Why?
|
| Peritoneal Stomata | 1 | 2015 | 3 | 0.540 |
Why?
|
| Patient Admission | 1 | 2015 | 53 | 0.530 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2014 | 12 | 0.510 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2014 | 37 | 0.500 |
Why?
|
| Abdominal Cavity | 1 | 2014 | 6 | 0.500 |
Why?
|
| Severity of Illness Index | 1 | 2017 | 863 | 0.500 |
Why?
|
| Gallbladder Neoplasms | 1 | 2014 | 33 | 0.490 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2014 | 32 | 0.490 |
Why?
|
| Laparoscopy | 3 | 2019 | 169 | 0.470 |
Why?
|
| Reoperation | 6 | 2017 | 203 | 0.470 |
Why?
|
| Ascites | 1 | 2013 | 13 | 0.470 |
Why?
|
| Urinary Tract | 1 | 2013 | 21 | 0.470 |
Why?
|
| Urologic Diseases | 1 | 2013 | 28 | 0.470 |
Why?
|
| Rectal Neoplasms | 1 | 2013 | 14 | 0.460 |
Why?
|
| Infusions, Parenteral | 5 | 2016 | 64 | 0.440 |
Why?
|
| Hepatectomy | 4 | 2018 | 66 | 0.430 |
Why?
|
| Extremities | 4 | 2019 | 48 | 0.420 |
Why?
|
| Adolescent | 8 | 2017 | 3254 | 0.410 |
Why?
|
| Risk Factors | 14 | 2019 | 3531 | 0.410 |
Why?
|
| Diabetes Mellitus | 1 | 2014 | 366 | 0.410 |
Why?
|
| Quality of Life | 5 | 2019 | 816 | 0.400 |
Why?
|
| Vena Cava, Inferior | 1 | 2009 | 31 | 0.360 |
Why?
|
| Cisplatin | 3 | 2014 | 69 | 0.360 |
Why?
|
| Abdominal Injuries | 1 | 2009 | 33 | 0.350 |
Why?
|
| Cystadenoma | 1 | 2009 | 2 | 0.350 |
Why?
|
| Biliary Tract Neoplasms | 1 | 2009 | 10 | 0.350 |
Why?
|
| Wounds, Gunshot | 1 | 2009 | 34 | 0.350 |
Why?
|
| Abdominal Pain | 1 | 2009 | 40 | 0.350 |
Why?
|
| Radiography, Thoracic | 2 | 2019 | 43 | 0.340 |
Why?
|
| Disease-Free Survival | 10 | 2018 | 281 | 0.340 |
Why?
|
| Soft Tissue Neoplasms | 2 | 2018 | 35 | 0.320 |
Why?
|
| Patient Readmission | 4 | 2016 | 105 | 0.320 |
Why?
|
| Anesthesia, Conduction | 2 | 2018 | 29 | 0.310 |
Why?
|
| Cohort Studies | 12 | 2019 | 1687 | 0.310 |
Why?
|
| Child | 4 | 2014 | 2219 | 0.310 |
Why?
|
| Propoxur | 1 | 2007 | 1 | 0.310 |
Why?
|
| Length of Stay | 5 | 2016 | 292 | 0.300 |
Why?
|
| Psychomotor Performance | 1 | 2008 | 97 | 0.300 |
Why?
|
| Insecticides | 1 | 2007 | 21 | 0.300 |
Why?
|
| Pancreatitis | 1 | 2007 | 18 | 0.300 |
Why?
|
| General Surgery | 1 | 2008 | 81 | 0.300 |
Why?
|
| Obesity | 2 | 2014 | 1063 | 0.290 |
Why?
|
| Multivariate Analysis | 5 | 2015 | 637 | 0.280 |
Why?
|
| Decision Support Techniques | 2 | 2018 | 104 | 0.280 |
Why?
|
| Blood Transfusion | 2 | 2017 | 64 | 0.280 |
Why?
|
| Preoperative Care | 4 | 2015 | 110 | 0.280 |
Why?
|
| Neoplasm Invasiveness | 6 | 2017 | 189 | 0.280 |
Why?
|
| Feasibility Studies | 2 | 2018 | 263 | 0.270 |
Why?
|
| Nomograms | 2 | 2016 | 30 | 0.270 |
Why?
|
| Carcinoma, Signet Ring Cell | 2 | 2015 | 6 | 0.260 |
Why?
|
| Blood Platelets | 2 | 2015 | 37 | 0.240 |
Why?
|
| Risk Assessment | 3 | 2018 | 1305 | 0.240 |
Why?
|
| Carboplatin | 2 | 2013 | 40 | 0.240 |
Why?
|
| Neutrophils | 2 | 2015 | 102 | 0.230 |
Why?
|
| Body Mass Index | 2 | 2016 | 865 | 0.220 |
Why?
|
| Neoadjuvant Therapy | 2 | 2019 | 56 | 0.220 |
Why?
|
| Proportional Hazards Models | 7 | 2017 | 709 | 0.210 |
Why?
|
| Cell Survival | 2 | 2019 | 272 | 0.200 |
Why?
|
| North Carolina | 2 | 2015 | 1423 | 0.190 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2019 | 871 | 0.190 |
Why?
|
| Neoplasm, Residual | 2 | 2016 | 23 | 0.180 |
Why?
|
| Meta-Analysis as Topic | 1 | 2019 | 39 | 0.180 |
Why?
|
| Neoplasm Metastasis | 2 | 2019 | 199 | 0.170 |
Why?
|
| Incidental Findings | 1 | 2018 | 26 | 0.170 |
Why?
|
| Thoracic Neoplasms | 1 | 2018 | 5 | 0.170 |
Why?
|
| Tumor Cells, Cultured | 1 | 2018 | 158 | 0.170 |
Why?
|
| Interinstitutional Relations | 1 | 2018 | 11 | 0.160 |
Why?
|
| Rare Diseases | 1 | 2018 | 20 | 0.160 |
Why?
|
| Thorax | 1 | 2018 | 27 | 0.160 |
Why?
|
| Incidence | 6 | 2016 | 1119 | 0.160 |
Why?
|
| Cooperative Behavior | 1 | 2018 | 73 | 0.160 |
Why?
|
| Melanoma | 1 | 2019 | 148 | 0.160 |
Why?
|
| Health Status | 2 | 2016 | 368 | 0.150 |
Why?
|
| Hospital Mortality | 2 | 2016 | 186 | 0.150 |
Why?
|
| Esophagogastric Junction | 1 | 2017 | 7 | 0.150 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2019 | 464 | 0.150 |
Why?
|
| Esophageal Neoplasms | 1 | 2017 | 33 | 0.150 |
Why?
|
| Skin Neoplasms | 1 | 2019 | 206 | 0.150 |
Why?
|
| Tumor Burden | 4 | 2017 | 60 | 0.140 |
Why?
|
| Mitotane | 1 | 2015 | 2 | 0.140 |
Why?
|
| Gastric Stump | 1 | 2015 | 2 | 0.140 |
Why?
|
| Helicobacter Infections | 1 | 2015 | 10 | 0.140 |
Why?
|
| Gastroenterostomy | 1 | 2015 | 2 | 0.140 |
Why?
|
| Anastomosis, Roux-en-Y | 1 | 2015 | 3 | 0.140 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2015 | 35 | 0.140 |
Why?
|
| Abdomen | 1 | 2016 | 42 | 0.140 |
Why?
|
| Jejunostomy | 1 | 2015 | 5 | 0.140 |
Why?
|
| Esophagectomy | 1 | 2015 | 15 | 0.140 |
Why?
|
| Case-Control Studies | 2 | 2014 | 859 | 0.130 |
Why?
|
| Patient Selection | 1 | 2017 | 257 | 0.130 |
Why?
|
| Immunoenzyme Techniques | 1 | 2015 | 46 | 0.130 |
Why?
|
| Forecasting | 1 | 2016 | 133 | 0.130 |
Why?
|
| Lung Neoplasms | 1 | 2019 | 384 | 0.130 |
Why?
|
| Enteral Nutrition | 1 | 2015 | 30 | 0.130 |
Why?
|
| Lymphocytes | 1 | 2015 | 53 | 0.130 |
Why?
|
| Anemia | 1 | 2015 | 55 | 0.130 |
Why?
|
| Drainage | 1 | 2015 | 49 | 0.130 |
Why?
|
| Intraoperative Care | 1 | 2015 | 48 | 0.130 |
Why?
|
| Cardia | 1 | 2014 | 1 | 0.130 |
Why?
|
| Skilled Nursing Facilities | 1 | 2014 | 9 | 0.130 |
Why?
|
| Time Factors | 2 | 2017 | 2001 | 0.130 |
Why?
|
| Chemoembolization, Therapeutic | 1 | 2014 | 9 | 0.130 |
Why?
|
| Injections, Intraperitoneal | 1 | 2014 | 41 | 0.130 |
Why?
|
| Frozen Sections | 1 | 2014 | 18 | 0.130 |
Why?
|
| Colectomy | 1 | 2014 | 25 | 0.120 |
Why?
|
| Pneumonia | 1 | 2014 | 61 | 0.120 |
Why?
|
| Omentum | 1 | 2014 | 26 | 0.120 |
Why?
|
| Perfusion | 1 | 2014 | 64 | 0.120 |
Why?
|
| Thrombosis | 1 | 2014 | 60 | 0.120 |
Why?
|
| Appendix | 1 | 2014 | 4 | 0.120 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2014 | 68 | 0.120 |
Why?
|
| Thiosulfates | 1 | 2013 | 3 | 0.120 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2014 | 79 | 0.120 |
Why?
|
| Respiratory Insufficiency | 1 | 2014 | 61 | 0.120 |
Why?
|
| Pseudomyxoma Peritonei | 1 | 2013 | 12 | 0.120 |
Why?
|
| Endosonography | 1 | 2014 | 56 | 0.120 |
Why?
|
| Ovariectomy | 1 | 2014 | 147 | 0.120 |
Why?
|
| Logistic Models | 4 | 2018 | 727 | 0.120 |
Why?
|
| Reconstructive Surgical Procedures | 1 | 2015 | 190 | 0.120 |
Why?
|
| Patient Discharge | 1 | 2014 | 168 | 0.120 |
Why?
|
| Propensity Score | 3 | 2019 | 34 | 0.120 |
Why?
|
| Ethnic Groups | 1 | 2016 | 440 | 0.110 |
Why?
|
| Disease Progression | 1 | 2014 | 572 | 0.110 |
Why?
|
| Analysis of Variance | 2 | 2015 | 454 | 0.100 |
Why?
|
| Drug Therapy, Combination | 1 | 2012 | 273 | 0.100 |
Why?
|
| European Continental Ancestry Group | 1 | 2016 | 1131 | 0.100 |
Why?
|
| Liver | 2 | 2015 | 464 | 0.100 |
Why?
|
| Medical Oncology | 1 | 2011 | 70 | 0.100 |
Why?
|
| Predictive Value of Tests | 3 | 2019 | 787 | 0.090 |
Why?
|
| Ligation | 1 | 2009 | 55 | 0.090 |
Why?
|
| Odds Ratio | 3 | 2015 | 447 | 0.090 |
Why?
|
| Amputation | 1 | 2009 | 37 | 0.090 |
Why?
|
| Leg | 1 | 2009 | 56 | 0.090 |
Why?
|
| Compartment Syndromes | 1 | 2009 | 38 | 0.090 |
Why?
|
| Age Factors | 3 | 2018 | 1108 | 0.090 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2009 | 9 | 0.090 |
Why?
|
| Mediastinal Cyst | 1 | 2007 | 3 | 0.080 |
Why?
|
| Cross-Over Studies | 1 | 2008 | 94 | 0.080 |
Why?
|
| Diagnosis, Differential | 1 | 2009 | 493 | 0.080 |
Why?
|
| Fluid Therapy | 1 | 2007 | 27 | 0.070 |
Why?
|
| Administration, Inhalation | 1 | 2007 | 92 | 0.070 |
Why?
|
| Mental Health | 2 | 2019 | 104 | 0.070 |
Why?
|
| Education, Medical, Undergraduate | 1 | 2008 | 84 | 0.070 |
Why?
|
| Computer Simulation | 1 | 2008 | 207 | 0.070 |
Why?
|
| Genetic Markers | 2 | 2018 | 122 | 0.070 |
Why?
|
| Education, Medical, Graduate | 1 | 2008 | 116 | 0.070 |
Why?
|
| Pain Measurement | 2 | 2018 | 364 | 0.070 |
Why?
|
| Blood Loss, Surgical | 2 | 2015 | 45 | 0.060 |
Why?
|
| Internship and Residency | 1 | 2008 | 283 | 0.060 |
Why?
|
| Rectal Diseases | 1 | 2002 | 3 | 0.060 |
Why?
|
| Cysts | 1 | 2002 | 16 | 0.060 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2019 | 23 | 0.040 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2019 | 69 | 0.040 |
Why?
|
| Retroperitoneal Space | 1 | 2018 | 18 | 0.040 |
Why?
|
| Hydrogels | 1 | 2019 | 103 | 0.040 |
Why?
|
| Health Care Costs | 1 | 2019 | 108 | 0.040 |
Why?
|
| Appendectomy | 1 | 2018 | 15 | 0.040 |
Why?
|
| Blood Cell Count | 1 | 2018 | 26 | 0.040 |
Why?
|
| Health Services Research | 1 | 2018 | 78 | 0.040 |
Why?
|
| Venous Thromboembolism | 1 | 2018 | 25 | 0.040 |
Why?
|
| ROC Curve | 1 | 2018 | 149 | 0.040 |
Why?
|
| Renal Insufficiency | 1 | 2018 | 53 | 0.040 |
Why?
|
| Postoperative Care | 1 | 2018 | 72 | 0.040 |
Why?
|
| Academic Medical Centers | 1 | 2018 | 150 | 0.040 |
Why?
|
| Cell Line, Tumor | 1 | 2019 | 680 | 0.040 |
Why?
|
| Recovery of Function | 1 | 2018 | 190 | 0.040 |
Why?
|
| Heart Diseases | 1 | 2017 | 97 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2018 | 532 | 0.040 |
Why?
|
| Emotions | 1 | 2016 | 48 | 0.040 |
Why?
|
| Pancreatic Fistula | 1 | 2016 | 3 | 0.040 |
Why?
|
| Extracellular Matrix | 1 | 2018 | 226 | 0.040 |
Why?
|
| Helicobacter pylori | 1 | 2015 | 9 | 0.030 |
Why?
|
| Postoperative Period | 1 | 2016 | 91 | 0.030 |
Why?
|
| Neoplasms, Second Primary | 1 | 2015 | 16 | 0.030 |
Why?
|
| Platelet Count | 1 | 2015 | 21 | 0.030 |
Why?
|
| Lymphocyte Count | 1 | 2015 | 23 | 0.030 |
Why?
|
| Hydrocortisone | 1 | 2015 | 61 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2015 | 128 | 0.030 |
Why?
|
| Stomach | 1 | 2015 | 16 | 0.030 |
Why?
|
| Cause of Death | 1 | 2015 | 220 | 0.030 |
Why?
|
| Spleen | 1 | 2015 | 82 | 0.030 |
Why?
|
| Colon | 1 | 2015 | 56 | 0.030 |
Why?
|
| Preoperative Period | 1 | 2014 | 31 | 0.030 |
Why?
|
| Pancreas | 1 | 2015 | 79 | 0.030 |
Why?
|
| Surgical Wound Infection | 1 | 2015 | 74 | 0.030 |
Why?
|
| Serum Albumin | 1 | 2014 | 53 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2015 | 320 | 0.030 |
Why?
|
| Comorbidity | 1 | 2015 | 540 | 0.030 |
Why?
|
| Tissue Engineering | 1 | 2019 | 608 | 0.030 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2011 | 20 | 0.030 |
Why?
|
| Track and Field | 1 | 2007 | 3 | 0.020 |
Why?
|
| Radiography | 1 | 2007 | 353 | 0.020 |
Why?
|
| Rectum | 1 | 2002 | 15 | 0.010 |
Why?
|